Full-Time

Maintenance Engineering Manager

Machine Shop & Asset Management

Deadline 8/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

San Angelo, TX, USA

In Person

On-site role; no remote work; up to 10% travel domestically/internationally.

Bachelor's

Category
Engineering Management
Required Skills
SAP Products

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Mechanical Engineering, Electrical Engineering, Manufacturing, Industrial Technology, or a related field is required; equivalent technical degree with substantial experience may be considered
  • A minimum of 6 years of progressive maintenance experience in a manufacturing or industrial environment is required
  • A minimum of 3 years of people management experience leading multi-disciplinary maintenance teams is required
  • Strong technical knowledge of mechanical, electrical, PLC controls, hydraulics, pneumatics, and machine tool maintenance is required
  • Hands-on understanding of machine shop operations, including CNC, lathes, mills, fabrication, and welding is required
  • Experience implementing and managing CMMS systems, such as SAP PM, Maximo, Infor, or similar platforms is required
  • Experience applying asset management best practices, including asset lifecycle planning, spare parts optimization, and data integrity is required
  • Demonstrated experience with reliability programs, including RCM, TPM, and structured root-cause analysis is required
  • Proven ability to manage budgets, labor allocation, maintenance spend, and capital projects is required
  • Strong communication and interpersonal skills with the ability to influence cross-functional stakeholders are required
Responsibilities
  • Lead, coach, and develop direct reports across Maintenance, Machine Shop, and Asset Management functions
  • Develop and execute maintenance strategies, including preventive, predictive, and reliability-centered maintenance, aligned with business goals
  • Oversee machine shop operations, including machining, fabrication, welding, and repair services to support production and capital projects
  • Manage the asset management program, including asset register, lifecycle planning, spare parts optimization, CMMS data integrity, and asset health monitoring
  • Establish and monitor key performance indicators, including equipment availability, MTTR, MTBF, OEE, maintenance cost per asset, preventive maintenance compliance, spare parts turnover, stockouts, and safety performance
  • Plan and manage maintenance budgets, labor allocation, spare parts inventory, and maintenance-related capital expenditures
  • Ensure compliance with safety, environmental, regulatory, and company standards while promoting a culture of safety, accountability, and continuous improvement
  • Coordinate major breakdown responses, root-cause analysis, and corrective action implementation
  • Partner with Production, Engineering, Quality, Procurement, and Supply Chain to support new equipment introductions, process changes, and capital projects
  • Select, manage, and evaluate external vendors and contractors to ensure quality, safety, compliance, and cost-effectiveness
  • Maintain accurate maintenance records in CMMS and produce timely reports for leadership
Desired Qualifications
  • Experience in regulated industries, such as medical devices, pharmaceuticals, or food and beverage manufacturing, is preferred
  • Familiarity with GMP, ISO, or other regulated manufacturing requirements is preferred
  • Experience implementing continuous improvement initiatives that measurably improved equipment reliability or reduced maintenance costs is preferred
  • Lean and/or Six Sigma certification is preferred

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion, and guidance lifted to $101.1 billion.
  • Tremfya grew 72.5% in Q2 2026, offsetting Stelara's patent loss.
  • OTTAVA's July 2026 launch plus ongoing hernia trials create a long runway for adoption.

What critics are saying

  • Stelara biosimilars and Medicare price cuts pressure immunology revenue throughout 2026.
  • Talc settlement still needs 95% claimant approval, and future lawsuits remain outside coverage.
  • Abiomed Impella weakness and surgeon skepticism threaten MedTech growth if Q3 volumes stay soft.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and consumer health, reducing single-product dependence.
  • OTTAVA gained FDA authorization on July 22, 2026, opening a new soft-tissue robotics category.
  • AAA credit status and 64-year dividend streak signal exceptional capital discipline.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 10th, 2026
J&J, Equinix, SBAC and one other stock could generate $2,304 annual passive income from $100K investment

Johnson & Johnson leads a portfolio of four dividend-growth stocks that together generate $2,304 in annual passive income from a $100,000 investment split equally. The group delivers a 2.30% blended yield. SBA Communications tops the quartet with a 2.58% yield. Johnson & Johnson brings a 64-year dividend streak and AAA credit rating, making it a core income holding. Equinix, which converted to a REIT in 2015, runs the world's largest neutral interconnection footprint. The company generated $2.63 billion in Q2 revenue and has grown its quarterly payout from $2.66 in 2020 to $5.16 today. Institutions own 99.6% of the float. All four stocks trade on major exchanges with tight spreads, offering liquidity advantages over alternatives like rental real estate or mortgage REITs.

Yahoo Finance
Aug 4th, 2026
JNJ returns $85B to shareholders but stock still lags S&P 500 by 13%

Johnson & Johnson returned $85 billion to shareholders over the past five years through $60 billion in dividends and $25 billion in share buybacks, equivalent to 13.8% of its current market capitalisation. The healthcare giant generated $97.93 billion in revenue over the last twelve months with a 27% operating margin. Despite this substantial cash return, JNJ shareholders saw a total return of 70% over five years, underperforming the S&P 500's 83% return. The company's Innovative Medicine division showed strong performance, with double-digit growth excluding STELARA and successful launches like ICOTYDE. However, the MedTech segment struggled, particularly in cardiovascular, where the Abiomed heart pump business saw sales decline 2%. The performance gap between divisions raises questions about whether returning cash signals disciplined capital allocation or a shortage of high-return growth opportunities.

Yahoo Finance
Jul 31st, 2026
J&J beats estimates with $25.3B revenue, raises guidance to $101.1B for the year

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.

Yahoo Finance
Jul 28th, 2026
J&J to pay $5.5B to settle 76,000 talc baby powder cancer lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle approximately 76,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. The settlement requires acceptance by at least 95% of claimants to take effect. The company expects to make an initial payment of no more than $3 billion in 2027, with additional payments due from 2028. Legal representatives suggest the total payout could reach $7 billion or more. The deal is designed to deliver payment to all claimants within 18 months and covers only current claims, leaving future lawsuits outside its scope. J&J maintains the claims lack merit but said the settlement allows it to move forward. The agreement follows three years of halted proceedings whilst J&J pursued unsuccessful bankruptcy strategies through a subsidiary. The company withdrew its talc-based baby powder from US shelves in 2020 and worldwide in 2023.

Yahoo Finance
Jul 27th, 2026
J&J's MedTech sales rise 4.5% to $8.93B in Q2 amid Abiomed weakness and electrophysiology pressure

Johnson & Johnson's MedTech segment delivered mixed second-quarter 2026 results. Sales rose 4.5% to $8.93 billion but missed the consensus estimate of $8.96 billion. The shortfall stemmed from weaker cardiovascular performance, particularly in Abiomed, where sales declined 2% due to slow procedural volumes for the Impella heart pump. Physician uncertainty following a UK study questioning Impella's benefit in certain high-risk procedures contributed to reduced usage. Despite cardiovascular weakness, J&J's Surgery, Vision, and Orthopedics businesses accelerated above expectations, growing 3.9%, 6.0%, and 4.9% respectively. Shockwave revenues rose 14.6% to $335 million. J&J characterised the Abiomed issue as temporary and noted stable overall procedure volumes across its MedTech business, with no meaningful impact from expired Affordable Care Act subsidies.